Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

• Main Authors: Jerry Bagel (Author), John Nia (Author), Peter W. Hashim (Author), Manmath Patekar (Author), Ana de Vera (Author), Sophie Hugot (Author), Kuan Sheng (Author), Summer Xia (Author), Isabelle Gilloteau (Author), Elisa Muscianisi (Author), Andrew Blauvelt (Author), Mark Lebwohl (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2018-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to ustekinumab in the phase 3b CLEAR study of moderate to severe plaque psoriasis. Here, we report 16-week results from CLARITY, a second head-to-head trial comparing secukin...